Abstract: 【Abstract】 Atopic dermatitis （AD） is a common chronic inflammatory skin disease with unclear pathogenesis. Multiple inflammatory cells and relevant cytokines are involved in its occurrence. Janus kinase（JAK） inhibitors can suppress the JAK-signal transducer and activator of transcription （STAT） signaling pathway, block the signal transduction of relevant cytokines, and reduce inflammatory responses. Currently, several JAK inhibitors have been approved for the treatment of moderate-to-severe AD, and clinical trials have demonstrated their good efficacy and safety. This review summarizes the mechanisms of action, efficacy and safety of different types of JAK inhibitors for the treatment of moderate-to-severe AD.

Key words: Dermatitis, atopic, Janus kinases, Signal transduction pathway, Efficacy, Safety